Biosplice Announced Collaboration with Novo Nordisk in Diabetes; Terms Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Biosplice Therapeutics has entered a collaboration with Novo Nordisk to develop drug candidates for diabetes treatment. Novo Nordisk will fund preclinical development and has an exclusive option to license Biosplice's intellectual property focused on cardiometabolic disorders. Financial terms were not disclosed.
June 13, 2024 | 10:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk has entered a collaboration with Biosplice Therapeutics to develop diabetes treatments, funding preclinical development with an exclusive licensing option.
The collaboration with Biosplice Therapeutics could enhance Novo Nordisk's diabetes treatment portfolio, potentially leading to new product developments and revenue streams.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80